2025年11月4日下午，港股市场生物科技板块出现整体下跌，昭衍新药（06127.HK）股价盘中大跌5.01%，引发市场关注。截至下午14时19分，该股报19.700港元/股，成交量300.051万股，换手率2.52%，振幅5.88%。
昭衍新药股价下跌的原因可能有以下几点：首先，生物科技行业整体表现疲软，板块跌幅达2.83%，对个股造成拖累。其次，资金流向数据显示，该股当日资金流出2760.91万港元，远超资金流入的1849.15万港元，表明投资者情绪谨慎。此外，公司目前市盈率高达184.58倍，估值偏高可能引发部分投资者担忧。
尽管如此，机构对昭衍新药的评级仍然偏正面。在6家参与评级的机构中，67%给予买入建议，17%给予持有建议，16%给予卖出建议。公司最新财报显示，营业收入为10.79亿港元，净利润8,839.85万港元，每股收益0.12港元。投资者在关注该股时，需要综合考虑行业趋势、公司基本面和市场情绪等多方面因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.